NO335441B1 - Anvendelse av en prostaglandinforbindelse til fremstilling av et farmasøytisk preparat for behandling av irritabel tarm-syndrom og/eller funksjonell dyspepsi - Google Patents

Anvendelse av en prostaglandinforbindelse til fremstilling av et farmasøytisk preparat for behandling av irritabel tarm-syndrom og/eller funksjonell dyspepsi Download PDF

Info

Publication number
NO335441B1
NO335441B1 NO20053623A NO20053623A NO335441B1 NO 335441 B1 NO335441 B1 NO 335441B1 NO 20053623 A NO20053623 A NO 20053623A NO 20053623 A NO20053623 A NO 20053623A NO 335441 B1 NO335441 B1 NO 335441B1
Authority
NO
Norway
Prior art keywords
ester
compound
prostaglandin
group
use according
Prior art date
Application number
NO20053623A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053623L (no
NO20053623D0 (no
Inventor
Ryuji Ueno
Sachiko Kuno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32717850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO335441(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NO20053623D0 publication Critical patent/NO20053623D0/no
Publication of NO20053623L publication Critical patent/NO20053623L/no
Publication of NO335441B1 publication Critical patent/NO335441B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20053623A 2002-12-27 2005-07-26 Anvendelse av en prostaglandinforbindelse til fremstilling av et farmasøytisk preparat for behandling av irritabel tarm-syndrom og/eller funksjonell dyspepsi NO335441B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43646202P 2002-12-27 2002-12-27
US43646302P 2002-12-27 2002-12-27
PCT/JP2003/016857 WO2004060377A1 (en) 2002-12-27 2003-12-26 Derivatives of prostaglandins for treating abdominal discomfort

Publications (3)

Publication Number Publication Date
NO20053623D0 NO20053623D0 (no) 2005-07-26
NO20053623L NO20053623L (no) 2005-09-26
NO335441B1 true NO335441B1 (no) 2014-12-15

Family

ID=32717850

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053623A NO335441B1 (no) 2002-12-27 2005-07-26 Anvendelse av en prostaglandinforbindelse til fremstilling av et farmasøytisk preparat for behandling av irritabel tarm-syndrom og/eller funksjonell dyspepsi

Country Status (15)

Country Link
US (3) US7795312B2 (cg-RX-API-DMAC7.html)
EP (2) EP2281564A3 (cg-RX-API-DMAC7.html)
JP (2) JP4889219B2 (cg-RX-API-DMAC7.html)
KR (2) KR20120045051A (cg-RX-API-DMAC7.html)
CN (1) CN1753680B (cg-RX-API-DMAC7.html)
AR (1) AR042670A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003292556B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0317740B8 (cg-RX-API-DMAC7.html)
CA (1) CA2510051C (cg-RX-API-DMAC7.html)
ES (1) ES2591252T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006981A (cg-RX-API-DMAC7.html)
NO (1) NO335441B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ541110A (cg-RX-API-DMAC7.html)
TW (1) TWI336254B (cg-RX-API-DMAC7.html)
WO (1) WO2004060377A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
ATE539756T1 (de) * 2002-10-23 2012-01-15 Sucampo Ag Prostaglandinsubstanzen für die behandlung von fettsucht
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
KR20140069182A (ko) * 2005-04-12 2014-06-09 수캄포 아게 위장 장애 치료를 위한 프로스타글란딘 화합물과 양성자 펌프 억제제의 병용
WO2008029949A1 (en) 2006-09-06 2008-03-13 Sucampo Ag Method and composition for promoting gastrointestinal bicarbonate secretion
EP2114411A2 (en) * 2007-02-27 2009-11-11 Sucampo AG Composition and method for protecting mitochondria
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
WO2011035142A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CN108685929A (zh) * 2012-04-23 2018-10-23 苏坎波公司 用于治疗具有腹泻的肠易激综合征的方法
AU2013331380B2 (en) 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
EP0455448B1 (en) 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
ES2310013T3 (es) * 1997-11-28 2008-12-16 Sucampo Ag Uso de compuestos de 15-ceto-prostaglandina e como antagonistas de endotelina.
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
DK1426361T4 (en) 1999-10-15 2015-03-16 Sucampo Ag Novel compounds containing a bi-cyclic compound and a glyceride
EP1267883B1 (en) * 2000-04-06 2009-06-17 Sucampo AG Bile secretion promoting composition for liver transplantation containing a 15-keto-prostaglandin
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
CA2445651C (en) * 2001-05-18 2011-08-09 Sucampo Ag Cathartic composition comprising halogenated prostaglandin derivatives
BR0212233A (pt) * 2001-08-31 2004-10-05 Sucampo Ag Abridor de canal de cloreto
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener

Also Published As

Publication number Publication date
BR0317740A (pt) 2005-11-22
KR101164838B1 (ko) 2012-07-11
AU2003292556B2 (en) 2009-09-10
BRPI0317740B1 (pt) 2018-09-18
KR20120045051A (ko) 2012-05-08
CN1753680B (zh) 2010-12-08
EP1575596B1 (en) 2016-06-22
NZ541110A (en) 2008-11-28
BRPI0317740B8 (pt) 2021-05-25
NO20053623L (no) 2005-09-26
TW200418491A (en) 2004-10-01
MXPA05006981A (es) 2005-12-14
US7795312B2 (en) 2010-09-14
AR042670A1 (es) 2005-06-29
JP2006513232A (ja) 2006-04-20
AU2003292556A1 (en) 2004-07-29
US20130217770A1 (en) 2013-08-22
ES2591252T3 (es) 2016-11-25
WO2004060377A1 (en) 2004-07-22
US20100298424A1 (en) 2010-11-25
JP2012031202A (ja) 2012-02-16
NO20053623D0 (no) 2005-07-26
US20040138308A1 (en) 2004-07-15
EP1575596A1 (en) 2005-09-21
CA2510051C (en) 2016-07-05
CA2510051A1 (en) 2004-07-22
TWI336254B (en) 2011-01-21
KR20050086950A (ko) 2005-08-30
JP4889219B2 (ja) 2012-03-07
CN1753680A (zh) 2006-03-29
EP2281564A3 (en) 2012-09-05
EP2281564A2 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
US20100298424A1 (en) Method for treating abdominal discomfort
CA2600331C (en) Use of 11-deoxy-prostaglandin for treating peripheral vascular diseases
CA2444103C (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
AU2008271982B2 (en) Pharmaceutical combination of NSAID and prostaglandin compound
NO340257B1 (no) 11-deoksyprostaglandinforbindelse og anvendelse derav til fremstilling av et preparat for behandling av en sentralnervesystemforstyrrelse hos et pattedyrindivid
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
JP5294559B2 (ja) クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物
US20030022933A1 (en) Method for providing a cathartic effect
CA2502439C (en) Prostaglandin compounds for the treatment of obesity

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees